Pharmaceutical Executive-01-01-2022

Industry experts convene for discussion on new quality management systems.

Government-led programs aim to attract scientists and offer resources to growing industry.

Pharma moves beyond promoting products to increase recognition of company names.

Employer-sponsored health plans create an increasingly cloudy path to access.

Standard for reaching patients shifts with influx of new technology in post-COVID world.

Pandemic lockdowns push pharma into brand-new era of social engagement.

Oncology and rare disease are ready to reap the benefits of COVID drug development.

Growing evidence supports psychoactive substances can successfully treat mental issues.

As borders shut down during the pandemic, pharma learned some lessons about sourcing.

Supply chain issues, psychedelic medicines, immunotherapies, social engagement, telemedicine, access barriers, corporate branding, and the rise of Chinese biotech are industry topics that deserve a closer look as we head into the future.

Myrtle Potter is no stranger to overcoming adversity. As CEO of Sumitovant Biopharma, she has used her entrepreneurship, determination, and inclusive attitude to help her persevere and achieve her highest goals while overseeing five companies—Myovant, Urovant, Enzyvant, Altavant, and Spirovant.

Brief summary of EY’s 2022 M&A Firepower report highlights trends.

Need for greater transparency and access fuels Big Tech’s presence.

The constantly evolving world of data is forcing pharma companies to implement new strategies for improved structure.

Questions grow over adding titles to the biopharma C-suite.

Looks to address disconnect between registration and reimbursement.

Progress in 2022 will require nimble action across several fronts.

Click the title above for a link to open the Pharmaceutical Executive January 2022 issue in an interactive PDF format.

Christopher J. Calhoun pulls back the curtain on the mysterious biotech funding process.